MiR-130a-3p Alleviates Liver Fibrosis by Suppressing HSCs Activation and Skewing Macrophage to Ly6Clo Phenotype

Front Immunol. 2021 Aug 5:12:696069. doi: 10.3389/fimmu.2021.696069. eCollection 2021.

Abstract

Emerging evidences have highlighted the crucial role of microRNAs (miRNAs) in the liver cirrhosis, but the relationship between miR-130a-3p and liver cirrhosis is not entirely clear. As we all know, schistosomiasis, as one of the zoonoses, can lead to liver cirrhosis when it advances. In this study, we investigated the biological functions of miR-130a-3p on the liver fibrosis of schistosomiasis in vivo and in vitro. The mice infected with Schistosoma japonicum (S. japonicum) were treated with lentivirus vector (LV)-miR-130a-3p by hydrodynamic injection through the tail vein. Our findings showed significantly decreased expression of miR-130a-3p both in the serum of patients with cirrhosis and in the liver of mice infected with S. japonicum. The results showed that LV-miR-130a-3p could effectively enter into the liver and alleviate liver granulomatous inflammation and collagen deposition. Simultaneously, LV-miR-130a-3p-promoted macrophages presented the Ly6Clo phenotype, concomitant with the decreased expression of the tissue inhibitor of metalloproteinases (TIMP) 1, and increased the expression of matrix metalloproteinase (MMP) 2, which contributed to the dissolution of collagen. Furthermore, overexpression of miR-130a-3p not only inhibited the activation and proliferation of hepatic stellate cells (HSCs) but also induced the apoptosis of HSCs. In addition, we also confirmed that miR-130a-3p enables to bind with mitogen-activated protein kinase (MAPK) 1 and transforming growth factor-beta receptors (TGFBR) 1 and TGFBR2 genes and inhibit the expressions of these genes. Our findings suggested that miR-130a-3p might represent as the potential candidate biomarker and therapeutic target for the prognosis identification and treatment of schistosomiasis liver fibrosis.

Keywords: HSCs; Ly6Clo; liver fibrosis; miR-130a-3p; schistosomiasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Ly / metabolism*
  • Apoptosis
  • Case-Control Studies
  • Cell Line
  • Cell Proliferation
  • Collagen Type I / metabolism
  • Disease Models, Animal
  • Female
  • Hepatic Stellate Cells / immunology
  • Hepatic Stellate Cells / metabolism*
  • Hepatic Stellate Cells / parasitology
  • Host-Parasite Interactions
  • Humans
  • Liver / immunology
  • Liver / metabolism
  • Liver / parasitology*
  • Liver Cirrhosis / immunology
  • Liver Cirrhosis / metabolism
  • Liver Cirrhosis / parasitology
  • Liver Cirrhosis / prevention & control*
  • Macrophages / immunology
  • Macrophages / metabolism*
  • Macrophages / parasitology
  • Mice
  • Mice, Inbred C57BL
  • MicroRNAs / administration & dosage*
  • MicroRNAs / genetics
  • MicroRNAs / metabolism
  • Phenotype
  • Schistosoma japonicum / immunology
  • Schistosoma japonicum / pathogenicity*
  • Schistosomiasis japonica / immunology
  • Schistosomiasis japonica / metabolism
  • Schistosomiasis japonica / parasitology
  • Schistosomiasis japonica / prevention & control*
  • Signal Transduction

Substances

  • Antigens, Ly
  • Collagen Type I
  • Ly-6C antigen, mouse
  • MIRN130 microRNA, human
  • MIRN130 microRNA, mouse
  • MicroRNAs